[CHARACTERISTICS OF NEW MESENCHYMAL STEM CELL LINE DERIVED FROM HUMAN EMBRYONIC STEM CELLS]

Area of Science:

• Cell Biology
• Stem Cell Research
• Genetics

Background:

• Human embryonic stem cells (ESC) are a source for generating mesenchymal stem cells (MSC).
• SC6-MSC, a novel fibroblast-like cell line, was derived from the human ESC line SC6.
• Karyotypic analysis revealed a hypodiploid karyotype (45, X0) in the SC6-MSC line.

Purpose of the Study:

• To characterize the novel SC6-MSC cell line derived from human ESC.
• To investigate the impact of the 45, X0 karyotype on SC6-MSC proliferation, surface marker expression, and differentiation potential.
• To assess the potential utility of SC6-MSC in regenerative medicine.

Main Methods:

• Karyotypic analysis for numerical and structural chromosomal abnormalities.
• Cell proliferation assays using growth curves and population doubling time.
• Flow cytometry and immunofluorescence for surface marker expression (CD44, CD73, CD90, CD105, HLA-ABC, CD34, HLA-DR, SSEA-4, TRA-1-60) and Oct-4.
• Directed differentiation assays for osteogenesis, chondrogenesis, and adipogenesis.

Main Results:

• SC6-MSC displayed a 45, X0 karyotype with reduced proliferative activity after passage 10.
• Expression of MSC markers (CD44, CD73, CD105, HLA-ABC) was detected, but CD90 and CD105 levels were lower than other MSC lines.
• Absence of Oct-4 and presence of SSEA-4 and TRA-1-60 were observed. Osteogenic and chondrogenic differentiation occurred, but adipogenic differentiation was absent.
• The 45, X0 karyotype likely contributes to the decreased differentiation potential and altered CD90 expression.

Conclusions:

• The SC6-MSC line, despite possessing some MSC characteristics, exhibits altered differentiation potential and surface marker expression due to its 45, X0 karyotype.
• The chromosomal imbalance may limit its application in regenerative medicine requiring robust adipogenic differentiation.
• Further research is needed to fully understand the implications of this karyotypic alteration for stem cell therapy.